Phaseline

Companies › TCRCure Biopharma

TCRCure Biopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TC-N201 cells
T cells genetically engineered with a TCR targeting NY-ESO-1
NY-ESO-1Phase 1Advanced Solid TumorsNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05881525TC-N201 cellsPhase 1Advanced Solid TumorsOncologyNov 2027

Targets

NY-ESO-1 (1)

Companies with the same targets

Takara Bio Guangzhou FineImmune Biotechnology

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.